NBRV - Nabriva Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.7200
+0.0600 (+2.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.6600
Open2.6700
Bid2.7100 x 3200
Ask2.7600 x 4000
Day's Range2.6200 - 2.7200
52 Week Range1.1200 - 6.0500
Volume644,099
Avg. Volume956,611
Market Cap189.583M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.2600
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
Trade prices are not sourced from all markets
  • PR Newswire9 days ago

    Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire10 days ago

    Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO™ (fosfomycin for injection) to Treat Complicated Urinary Tract Infections (cUTIs)

    DUBLIN, Ireland, April 11, 2019 -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat.

  • Do Options Traders Know Something About Nabriva Therapeutics (NBRV) Stock We Don't?
    Zacks16 days ago

    Do Options Traders Know Something About Nabriva Therapeutics (NBRV) Stock We Don't?

    Investors need to pay close attention to Nabriva Therapeutics (NBRV) stock based on the movements in the options market lately.

  • Nabriva Therapeutics (NBRV) in Focus: Stock Moves 7.5% Higher
    Zacks17 days ago

    Nabriva Therapeutics (NBRV) in Focus: Stock Moves 7.5% Higher

    Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • GlobeNewswire19 days ago

    Nabriva Therapeutics to Present at the Needham and Company 18th Annual Healthcare Conference

    DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 02, 2019 -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative.

  • GlobeNewswire20 days ago

    Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 41,150 ordinary shares of Nabriva Therapeutics as inducements to four newly-hired employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation. The stock options were granted effective March 31, 2019 with an exercise price of $2.44 per share, which is equal to the closing price of Nabriva Therapeutics’s ordinary shares on March 29, 2019, which was the last trading day prior to the date of grant.

  • GlobeNewswirelast month

    Nabriva Therapeutics Reports 2018 Financial Results and Recent Corporate Highlights

    - Two PDUFA dates in 2019: April 30, 2019 for CONTEPO and August 19, 2019 for Lefamulin -- Company preparing for potential commercialization of two first-in-class.

  • GlobeNewswire2 months ago

    Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults

    Nabriva Therapeutics plc (NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Applications (NDAs) and granted a priority review for both the intravenous (IV) and oral formulations of lefamulin, a potentially first-in-class, semi-synthetic pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia (CABP). The acceptance of lefamulin’s two NDAs indicates that the FDA has deemed both applications sufficiently complete to allow a substantive review. Both applications have been granted priority review and the Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA’s review is August 19, 2019.

  • PR Newswire3 months ago

    Antimicrobials Working Group Announces Updates to Leadership Team

    WASHINGTON , Jan. 17, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh , M.D., President, Chief Operating Officer and Chief Medical ...

  • Nabriva Therapeutics (NBRV) Jumps: Stock Rises 6.7%
    Zacks3 months ago

    Nabriva Therapeutics (NBRV) Jumps: Stock Rises 6.7%

    Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • GlobeNewswire3 months ago

    Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on January 23, 2019

    The event will feature a discussion with leading clinicians and researchers who will address current and potential new treatments for community-acquired bacterial pneumonia (CABP)and complicated urinary tract infections (cUTIs). Nabriva management will also discuss the commercial strategy for the company’s investigational antibiotics, lefamulin and CONTEPO™, followed by a panel Q&A. Lefamulin and CONTEPO are potential first-in-class antibiotics in the United States.

  • GlobeNewswire3 months ago

    Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™

    Nabriva Therapeutics plc (NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced that the U.S. Food and Drug Administration (FDA) has updated the PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA’s review of the CONTEPO New Drug Application (NDA) from June 30, 2019 to April 30, 2019.  The two-month acceleration is due to a clarification of the classification and subsequent expedited review period for the CONTEPO NDA submitted in October 2018. In addition to priority review, CONTEPO has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of several serious infections, including cUTI.

  • GlobeNewswire4 months ago

    Nabriva Therapeutics Announces Acceptance of the New Drug Application for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections by FDA

    Nabriva Therapeutics plc (NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted a priority review for CONTEPO™ (fosfomycin for injection) to treat complicated urinary tract infections (cUTIs), including acute pyelonephritis. The acceptance of the NDA indicates that the FDA has deemed the application sufficiently complete to allow a substantive review.

  • Antibiotic developer Nabriva enters into $75M loan deal
    American City Business Journals4 months ago

    Antibiotic developer Nabriva enters into $75M loan deal

    Under the terms of the debt financing, Nabriva will receive $25 million right away and up to another $50 based on receiving FDA new product approvals for two experimental therapies — and then hitting sales goals for those products.

  • GlobeNewswire4 months ago

    Nabriva Therapeutics Announces Closing of up to a $75 million Term Loan

    Nabriva Therapeutics plc (NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, today announced the closing of up to a $75 million term loan with Hercules Capital, Inc. (HTGC) (“Hercules”), $25 million of which was funded on the day of closing.

  • Nabriva files 2 NDAs seeking approval for experimental pneumonia treatment
    American City Business Journals4 months ago

    Nabriva files 2 NDAs seeking approval for experimental pneumonia treatment

    The King of Prussia company is seeking approval for both an intravenous and oral version of its antibiotic to treat community-acquired bacterial pneumonia.

  • GlobeNewswire4 months ago

    Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults

    Nabriva Therapeutics plc (NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the oral and intravenous (IV) formulations of lefamulin, a first-in-class, semi-synthetic pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia (CABP). Both formulations of lefamulin were granted Qualified Infectious Disease Product and Fast Track designation by the FDA, enabling potential Priority Review of the NDAs by the FDA.  Nabriva Therapeutics plans to submit a marketing authorization application for lefamulin in Europe in the first quarter of 2019.

  • GlobeNewswire5 months ago

    Nabriva Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

    Nabriva Therapeutics plc (NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer, will provide a company overview and business update at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 11:10 a.m. ET. Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics has two product candidates that are in late stage development: lefamulin, under development to potentially be the first pleuromutilin antibiotic available for systemic administration in humans, and CONTEPO, a potential first-in-class in the United States, hospital-based intravenous, or IV, antibiotic.

  • GlobeNewswire5 months ago

    Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

    - New Drug Application for CONTEPO™ submitted to FDA in October 2018 -- Company preparing for potential commercialization of two, first-in-class antibiotics,Lefamulin (IV and.

  • Nabriva files new drug application with FDA for urinary tract infection drug
    American City Business Journals6 months ago

    Nabriva files new drug application with FDA for urinary tract infection drug

    Nabriva acquired the new drug candidate, called Contepo, as part of its purchase of Zavante Therapeutics in a stock deal valued at about $27 million.

  • GlobeNewswire6 months ago

    Nabriva Therapeutics Completes Submission of New Drug Application to U.S. Food and Drug Administration for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections

    DUBLIN, Ireland, Nov. 01, 2018 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) to seek marketing approval for its investigational intravenous antibiotic, CONTEPO™ (fosfomycin for injection) to treat complicated urinary tract infections (cUTIs), including acute pyelonephritis. CONTEPO has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of several serious infections, including cUTI, which enables Priority Review of the NDA, following acceptance. “A significant medical need remains in the United States for new treatments for complicated urinary tract infections as serious Gram-negative infections caused by extended-spectrum beta-lactamase (ESBLs) producing Enterobacteriaceae, as well as other multi-drug resistant pathogens, continue to be a significant challenge for healthcare providers leading to treatment failure, infection recurrence, re-hospitalizations, and higher rates of morbidity and mortality,” said Dr. Jennifer Schranz, chief medical officer of Nabriva Therapeutics.

  • Implied Volatility Surging for Nabriva Therapeutics plc (NBRV) Stock Options
    Zacks7 months ago

    Implied Volatility Surging for Nabriva Therapeutics plc (NBRV) Stock Options

    Investors need to pay close attention to Nabriva Therapeutics (NBRV) stock based on the movements in the options market lately.